Novacyt

Novacyt Gross Profit

The Gross Profit of Novacyt (ALNOV.PA) as of Oct 24, 2026 is 7.89 M GBP. In the previous year, Gross Profit was 32.07 M GBP — a change of -75.41% (lower).

Gross Profit

7.89 MGBP

YoY

-75.41%

Last updated:

Gross Profit of Novacyt is 2025 7.89 M GBP. Gross Profit of Novacyt was 2024 32.07 M GBP. It decreases by -75.41% lower compared to the previous year.

The Novacyt Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Profit
Date
Gross Profit
Jan 1, 2018
6.40 M GBP
Jan 1, 2019
6.20 M GBP
Jan 1, 2020
211.13 M GBP
Jan 1, 2021
63.50 M GBP
Jan 1, 2022
5.75 M GBP
Jan 1, 2023
3.73 M GBP
Jan 1, 2024
32.07 M GBP
Jan 1, 2025
7.89 M GBP
The Novacyt Gross Profit history
YEARGross ProfitYoY
7.89 MGBP-75.41%
32.07 MGBP+759.89%
3.73 MGBP-35.09%
5.75 MGBP-90.95%
63.50 MGBP-69.92%
211.13 MGBP+3,303.51%
6.20 MGBP-3.10%
6.40 MGBP+6.04%
6.04 MGBP+20.97%
4.99 MGBP+43.55%
3.48 MGBP+130.47%
1.51 MGBP+222.20%
468,198.70GBP+236.31%
139,218.12GBP+197.19%
46,844.38GBP-111.51%
-407,063.28GBP-46.67%
-763,221.30GBP—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Novacyt Revenue

Novacyt Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
277.20 M GBP
167.44 M GBP
132.42 M GBP
Jan 1, 2021
92.60 M GBP
-3.92 M GBP
-9.73 M GBP
Jan 1, 2022
21.04 M GBP
-23.39 M GBP
-25.73 M GBP
Jan 1, 2023
11.58 M GBP
-29.52 M GBP
-28.29 M GBP
Jan 1, 2024
19.63 M GBP
-37.34 M GBP
-41.76 M GBP
Jan 1, 2025
20.40 M GBP
-13.18 M GBP
-23.31 M GBP
Jan 1, 2026 (e)
30.53 M GBP
-16.40 M GBP
-8.86 M GBP
Jan 1, 2027 (e)
34.86 M GBP
-18.70 M GBP
-4.96 M GBP

Novacyt Margins

Novacyt stock margins

The Novacyt margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Novacyt. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Novacyt.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
76.16 %
60.40 %
47.77 %
Jan 1, 2021
68.57 %
-4.23 %
-10.51 %
Jan 1, 2022
27.31 %
-111.18 %
-122.29 %
Jan 1, 2023
32.21 %
-254.91 %
-244.34 %
Jan 1, 2024
163.39 %
-190.23 %
-212.73 %
Jan 1, 2025
38.65 %
-64.58 %
-114.25 %
Jan 1, 2026 (e)
38.65 %
-53.73 %
-29.03 %
Jan 1, 2027 (e)
38.65 %
-53.64 %
-14.23 %

Novacyt Stock analysis

What does Novacyt do? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novacyt stock

Gross Profit of Novacyt is 7.89 M GBP in 2025.

Gross Profit of Novacyt changed from 32.07 M GBP to 7.89 M GBP, representing a -75.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit Novacyt since 2006 – with annual values, charts, and detailed analysis.

Gross Profit is the revenue remaining after deducting the cost of goods sold. It shows how efficiently a company uses its resources to produce goods or services.

Gross Profit's GBP is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Gross Profit's Novacyt historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Novacyt

All Key Metrics — Novacyt